Peroxisome proliferator activated receptor agonists

Details Peroxisome proliferator activated receptor agonists Peroxisome proliferator activated receptor agonists

2002-11-26

2009-06-09

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S323500, C514S398000

Reexamination Certificate

active

07544812

ABSTRACT:
The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-C6cycloalkylaryl-C0-2-alkyl, and —CH2—C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C1-C6alkyl, C1-C6alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-C4alkyl sulfonamide, C1-C4alkyl amide, OR10 and C3-C6cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C1-C5alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH2)n COOR19.

REFERENCES:
patent: 3452041 (1969-06-01), Bell et al.
patent: 4241073 (1980-12-01), Jamieson et al.
patent: 27 24 948 (1977-12-01), None
patent: 0 005 647 (1979-11-01), None
patent: WO 97 31907 (1997-09-01), None
patent: WO 98 39303 (1998-09-01), None
patent: WO 01 16120 (2001-03-01), None
Swain, CA 43:1769b-h, 1949.
Burton et al., CA 43:6978d-g, 1949.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.
Vippagunta et al., Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
Colagiuri et al., American Journal of Public Health, Sep. 2006, vol. 96, No. 9, pp. 1562-1569.
Bruno et al., Expert Opinion Emerging Drugs, (2005), 10(4), pp. 747-771.
Park, Diabetes Research and Clinical Practice 66S (2004), S33-S35.
Curtis et al., The Journal of the American Board of Family Practice, vol. 18, pp. 37-43, (2005).
J. Knabe, et al.: “Razemate und Enantiomere Basich Substituierter 5-Phenylhtdabtoine, Synthese und Antiarrhythmische Wirkung”: Pharmazeutische, vol. 52, (1997), pp. 912-919.
Stanley C. Bell, et al.: “Rearrangement Reactions of Phenyl Chloroformate Derivatives of 2-hydroxyaminoacetanilides to Hydantoins, Ureas and Hydantoic Acid Derivatives”: Journal of Heterocyclic Chemistry, vol. 13, No. 1, (1976), pp. 51-55.
Joseph Weinstock, et al.: “Synthesis of a 10,10a-dihydro-1H-imidazo-(3, 4-b)(1, 2)benzothianzine 5,5-dioxide”: Journal of Organic Chemistry, vol. 33, No. 8, (1968), pp. 3342-3343.
Walfredd S. Sarr, et al.: “Tyrosine Hydrolase Inhibitors. Synthesis and Activity of Substituted Aromatic Amino Acids”: Journal of Medicinal Chemistry, vol. 10, No. 6, (1967), pp. 1008-1014.
Steiman, David M., et al.: “Synthesis of Side Chain-protected Amino Acid Phenyithiohydantoins and Their Use in Quantitative Solid-phase Edman Degradation”: Chemical Abstracts, vol. 102, No. 17, Apr. 29, 1985, Columbus, OH, U.S.: Abstract No. 145646z.
Kent, Stephen B. H., et al.: “A Study of the Edman Degradation in the Assessment of the Purity of Synthetic Peptides”: Chemical Abstracts, vol. 99, No. 3, Jul. 18, 1983, Columbus, OH: Abstract No. 22893q.
Robert C. Glen, et al.: “Computer-aided Design and Synthesis of 5-sbustituted Tryptamines and Their Pharmacology at the 5-HTID Receptor: Discovery of Compounds with Potential Anti-migraine Properties”: Journal of Medicinal Chemistry, vol. 38, No. 18, (1995), pp. 3566-3580.
Donald L. Ross, et al.: “N-(gamma-L-Glutamyl)aminobenzioic Acids”: Journal of Medicinal Chemistry, vol. 6, (1963), pp. 208-210.
Silver Halide Color Photographic Material: Chemical Abstracts, vol. 102, No. 12, Mar. 25, 1985, Columbus, OH, U.S.: Abstract No. 103450a.
Jandu, Karamjit Singh, et al.: “Discovery of 4-(3-trans-3-dimethylaminocyclobutyl)-1H-indiol-5-ylmethyl)-(4S)-oxazolidin-2-one(4991W93), a 5HT1H//1D Receptor Partial Agonist and a Potent Inhibitor of Electrically Induced Plasma Extravasation”: Chemical Abstracts, vol. 134, 2001, Columbus, OH, US: Abstract No. 246873n.

Affiliated with

Also associated with

Rating

Peroxisome proliferator activated receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peroxisome proliferator activated receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peroxisome proliferator activated receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132975